Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Part of paid clinical trials in Kansas City, Kansas.

Sponsor
University of Kansas Medical Center
Study ID
NCT06364176
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Cystic Fibrosis

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Losartan — DRUG
    Treatment with losartan through week 12
  • Placebo — DRUG
    Treatment with placebo through week 12

Study Details

The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator therapy. Participants will be asked take losartan or placebo for twelve weeks and will have changes in sweat chloride levels measured as a marker of CFTR function.

Key Dates

Start date
Jun 3, 2024
Status verified
Apr 2025
Primary completion
May 31, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
42 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Losartan
    Losartan 25mg twice daily for one week followed by 50mg twice daily through week 12.
  • Placebo Comparator: Placebo
    Placebo twice daily through week 12

Primary Outcome Measure

Sweat chloride [ Time Frame: Baseline through week 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Kansas Medical CenterKansas CityKansas66160
Charles Bengtson, MD, MSc
913-588-6000
Carolina Aguiar
9139459295
Matthias Salathe, M.D. (SUB_INVESTIGATOR)
Andreas Schmid, M.D. (SUB_INVESTIGATOR)

Find similar trials in Kansas City, KS

By research site
University of Kansas Medical Center· Kansas City, KS

Related Studies